Controversy Surrounding E-Cigarettes as Smoking Cessation Tool

Jan.10.2023
Controversy Surrounding E-Cigarettes as Smoking Cessation Tool
A study claims e-cigarettes do not help smokers quit, but experts criticize its design and potential bias.

In December of last year, the UK's Office for National Statistics (ONS) confirmed the "key role" that e-cigarettes have played in driving smoking rates in the country to their lowest point in history. However, a study published in the Tobacco Control journal shortly after claims that e-cigarettes are not effective tools for quitting smoking. This report has come under criticism from experts and the UK Vaping Industry Association (UKVIA).


This study has sparked a headline in the Daily Mail claiming "study finds e-cigarettes cannot help people quit regular cigarettes." The headline came just seven days after the UK encouraged smokers to switch to e-cigarettes as a means of quitting traditional smoking.


A record-breaking 4 million people in the UK are now using electronic cigarettes, according to the UK National Statistics Office. This widespread shift towards e-cigarettes is believed to be partially responsible for a decrease in the smoking rate in the UK to just 13.3% - the lowest recorded figure to date.


Professor Peter Hajek from Queen Mary University of London states that the conclusion 'e-cigarettes have not made a significant contribution to smoking cessation among the population' cannot be drawn from the available data.


A new study from George Washington University in the United States focuses on "dual users" - people who smoke cigarettes and use electronic cigarettes. The study analyzed data from 2013 to 2019 and concluded that "before 2019, the use of electronic nicotine delivery systems (ENDS) did not contribute to substantial smoking cessation at the population level.


The authors of the study stated that their findings "suggest that reducing smoking can help dual users quit using both products," but critics argue that the study has limitations.


Dr. Sarah Jackson, Head Researcher of the Tobacco and Alcohol Research Group at University College London (UCL), stated that this study did not assess whether or not e-cigarettes help smokers quit smoking.


To determine whether using electronic cigarettes can help people quit smoking, we need to study the difference in smoking cessation rates between users of electronic cigarettes and non-users.


Other studies have already done so, using observational and experimental research designs, and indicate that smokers who attempt to quit smoking using e-cigarettes are more likely to succeed.


The UKVIA believes that vaping can aid smokers in quitting | Source: moffitt.org


Professor John Britton, esteemed epidemiologist at the University of Nottingham, stated, "The design of this study selected individuals who either found it difficult to quit smoking or did not want to quit. In this scenario, the good news is that some individuals were able to achieve success.


This study cannot tell us whether smokers who become dual users are more successful at quitting smoking than smokers who do not become dual users.


Therefore, the message of this paper is that quitting smoking is very difficult, but using electronic cigarettes may help you achieve it. Saying that e-cigarettes can stop you from quitting smoking in the "real world" is incorrect.


Peter Hajek, the director of the Tobacco Dependence Research Unit at Queen Mary University of London, stated that the conclusion that "e-cigarettes make no significant contribution to people quitting smoking" cannot be drawn from the data.


This study focused only on individuals who did not quit smoking and became "dual users" of e-cigarettes, excluding those who quit smoking altogether. Despite the selection of individuals who did not immediately receive full benefits, more than 25% of dual users actually quit smoking.


Excluding those who completely switch to using e-cigarettes and only evaluating their effectiveness on those who become dual users presents a serious methodological problem. It is like picking the best apples from a fertilized orchard, measuring the remaining apples, and declaring that the fertilizer is ineffective.


The tobacco control press release is particularly misleading. It claims that dual use is harmful, but in reality it is associated with reduced smoking and subsequent smoking cessation, making it actually beneficial. It also asserts that the study found e-cigarettes do not help smokers quit more easily, but the paper did not make such a statement.


Professor Robert West, Honorary Professor of Health Psychology at University College London, stated that "this study cannot resolve whether e-cigarettes at a population level help or hinder smoking cessation, but this conclusion may be temporary - so it is surprising to see such a statement from a reputable scientific journal.


A recent study on population trends reveals that individuals attempting to quit smoking are more likely to succeed if they use electronic cigarettes. Moreover, the increasing use of electronic cigarettes in the population is positively correlated with an increase in successful attempts to quit smoking over time.


This confirms strong evidence from randomized trials in which smokers were randomly assigned to receive either electronic cigarettes or products such as nicotine patches, gum, and lozenges. These studies clearly demonstrate that electronic cigarettes are superior.


The press release claims that data suggests the use of e-cigarettes may not be helpful in aiding a sample population to quit smoking, which is particularly surprising given that at the start of the research, individuals who used e-cigarettes daily were more likely to quit smoking in the following two years compared to non-daily users. This is contrary to the direction they seem to be asserting.


John Dunne, the Director General of UKVIA, stated, "No wonder smokers are feeling confused when faced with such mixed messages.


At a recent vaping summit in London, Rosanna O'Connor from the Health Improvement and Differentiation Office advised attendees not to always trust what they read in the media. I fully agree with her statement.


When the same newspaper tells you one day how e-cigarettes can help people quit smoking in the UK, and then contradicts itself the next day, it may seem amusing, but there is a serious point to be made here.


Misinformation about e-cigarettes has prevented smokers from switching to e-cigarettes, which in turn means that lives will continue to be unnecessarily lost due to deadly combustible cigarettes.


When the UK Office for National Statistics expresses enough confidence to say that electronic cigarettes have played a "major role" in reducing smoking rates in the UK, we can be certain that this is true.


If anyone truly doubts whether e-cigarettes can really help people quit smoking, they can ask any of the country's four million e-cigarette users for their thoughts!



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11